# Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial

> **NCT07432516** · NA · NOT_YET_RECRUITING · sponsor: **Yonsei University** · enrollment: 4400 (estimated)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** Discontinuation strategy + Combination lipid-lowering therapy
- **DRUG:** Switching strategy + Combination lipid-lowering therapy
- **DRUG:** Discontinuation strategy + High-intensity statin therapy
- **DRUG:** Switching strategy + High-intensity statin therapy

## Key facts

- **NCT ID:** NCT07432516
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2033-06
- **Final completion:** 2033-06
- **Target enrollment:** 4400 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07432516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07432516, "Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07432516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*